Arrowhead Pharmaceuticals Inc. (ARWR)

30.88
NASDAQ : Health Technology
Prev Close 32.12
Day Low/High 30.71 / 32.73
52 Wk Low/High 10.41 / 35.41
Avg Volume 1.79M
Exchange NASDAQ
Shares Outstanding 95.30M
Market Cap 3.06B
EPS -0.70
P/E Ratio 69.83
Div & Yield N.A. (N.A)

Latest News

Arrowhead Pharmaceuticals To Webcast Fiscal 2019 Third Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2019 Third Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2019, at 4:30 p.

Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-ANG3

Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-ANG3

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the U.

Arrowhead Pharmaceuticals To Participate In Roth RNA Revolution Conference

Arrowhead Pharmaceuticals To Participate In Roth RNA Revolution Conference

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Bruce Given, M.

PepsiCo, Blackstone, Grocery Outlet: 'Mad Money' Lightning Round

PepsiCo, Blackstone, Grocery Outlet: 'Mad Money' Lightning Round

Jim Cramer takes a look at PepsiCo, Blackstone, Grocery Outlet Holding Corp. Mastec, International Paper, Arrowhead Pharma, Organigram Holdings and more.

Arrowhead Pharmaceuticals Receives Fast Track Designation For ARO-AAT For Treatment Of Alpha-1 Liver Disease

Arrowhead Pharmaceuticals Receives Fast Track Designation For ARO-AAT For Treatment Of Alpha-1 Liver Disease

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the U.

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 14, 2019, the Compensation Committee of the Board of Directors approved "inducement" grants to 11 new employees under...

Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-APOC3

Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-APOC3

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.

Arrowhead Pharmaceuticals To Present At Upcoming June 2019 Conferences

Arrowhead Pharmaceuticals To Present At Upcoming June 2019 Conferences

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies 2019 Global Health Care Conference - New York, June 4-7, 2019 June 6, 9:30 a.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARWR, DBI, DLTR, NATR, RRGB Downgrades: AFI, CHMI, DVD, ENS, MTX, R, RTW, URBN Initiations: BFST, MGY, SURF, ZS, ZUO Read on to get TheStreet Quant Ratings' detailed report:

Kontoor Brands And Arrowhead Pharmaceuticals Set To Join S&P SmallCap 600

Kontoor Brands And Arrowhead Pharmaceuticals Set To Join S&P SmallCap 600

NEW YORK, May 20, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the open of trading on Friday, May 24: Kontoor Brands Inc.

Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results

Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2019 second quarter ended March 31, 2019.

Arrowhead Pharmaceuticals To Present At Upcoming May 2019 Conferences

Arrowhead Pharmaceuticals To Present At Upcoming May 2019 Conferences

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Bank of America Merrill Lynch 2019 Health Care Conference - Las Vegas, May 14-16, 2019 May 15, 8:40 a.

What Goes Up: Cramer's 'Mad Money' Recap (Wednesday 5/1/19)

What Goes Up: Cramer's 'Mad Money' Recap (Wednesday 5/1/19)

Jim Cramer says it's not 1987 or 1999, and there's no reason to dump stocks right now, but he does advocate discipline and caution.

Kohl's, Exxon Mobil, Delta Air Lines: 'Mad Money' Lightning Round

Kohl's, Exxon Mobil, Delta Air Lines: 'Mad Money' Lightning Round

Jim Cramer weighs in on Kohl's, Exxon Mobil, Delta Air Lines, Allergan, Arrowhead Research, Wayfair, Varonis Systems and more.

Arrowhead Pharmaceuticals To Webcast Fiscal 2019 Second Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2019 Second Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 8, 2019, at 4:30 p.

Arrowhead Begins Triple Combination Cohort In Chronic HBV Patients And Earns $25 Million Milestone Payment From Janssen

Arrowhead Begins Triple Combination Cohort In Chronic HBV Patients And Earns $25 Million Milestone Payment From Janssen

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has begun dosing in a new triple combination cohort (cohort 12) that includes JNJ-3989 (formerly ARO-HBV) and additional undisclosed agents selected by Janssen Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Receives FDA Clearance To Begin Phase 2/3 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

Arrowhead Pharmaceuticals Receives FDA Clearance To Begin Phase 2/3 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received clearance from the U.

Arrowhead Presents Clinical Data On JNJ-3989 (ARO-HBV) At The International Liver Congress™

Arrowhead Presents Clinical Data On JNJ-3989 (ARO-HBV) At The International Liver Congress™

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the presentation of clinical data from an ongoing Phase 1/2 study (AROHBV1001) of JNJ-3989 (formerly ARO-HBV), a third-generation subcutaneously administered RNA interference (RNAi)...

Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents And Reverses Alpha-1 Liver Disease At The International Liver Congress™

Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents And Reverses Alpha-1 Liver Disease At The International Liver Congress™

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at The International Liver Congress™ 2019 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), demonstrating that sustained reduction of...

Interesting ARWR Put And Call Options For May 17th

Interesting ARWR Put And Call Options For May 17th

Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 22, 2018, the Compensation Committee of the Board of Directors approved "inducement" grants to 7 new employees under...

Arrowhead Pharmaceuticals Files IND For Pivotal Phase 2/3 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

Arrowhead Pharmaceuticals Files IND For Pivotal Phase 2/3 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.

Arrowhead Pharmaceuticals Begins Dosing In Phase 1 Study Of ARO-APOC3 For Treatment Of Hypertriglyceridemia

Arrowhead Pharmaceuticals Begins Dosing In Phase 1 Study Of ARO-APOC3 For Treatment Of Hypertriglyceridemia

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being developed for the treatment...

Arrowhead Pharmaceuticals To Present At Upcoming March 2019 Conferences

Arrowhead Pharmaceuticals To Present At Upcoming March 2019 Conferences

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: Barclays Global Healthcare Conference 2019 - Miami, March 12-14, 2019 March 12, 4:20 p.

Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results

Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2019 first quarter ended December 31, 2018.

Interesting ARWR Put And Call Options For September 20th

Interesting ARWR Put And Call Options For September 20th

Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the September 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Pharmaceuticals To Webcast Fiscal 2019 First Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2019 First Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 7, 2019, at 4:30 p.

Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-APOC3 For Treatment Of Hypertriglyceridemia

Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-APOC3 For Treatment Of Hypertriglyceridemia

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being developed...

TheStreet Quant Rating: C+ (Hold)